December 1, 2022 C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmac
November 30, 2022 eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Implementing Numeric Rating and Visual Analog Scales in an eCOA Soluti
November 16, 2022 The culture of research communication in neonatal intensive care units: key stakeholder perspectives
November 16, 2022 Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital heath technologies
November 15, 2022-November 17, 2022 Selecting Outcomes That Are Truly Meaningful to Patients Panel discussion at the National Organization of Rare Disorders (NORD) Breakthrough Summit in Washington, DC, held October 15 –
November 15, 2022 C-Path and Cerveau Technologies, Inc. Announce Data Sharing Collaboration to Accelerate Drug Development for Alzheimer’s Disease and Related Dementias TUCSON, Ariz., November 15, 2022 — The Critical Path for Alzheimer’s Disease (CPAD) at the Critical Path Institute (C-Path) an
November 14, 2022-November 15, 2022 10th Annual Drug Repositioning & Repurposing Conference November 14-15, Washington, DC Join us at the 10TH ANNUAL DRUG REPOSITIONING AND REPURPOSING CONFERENCE, where attendees will mee
November 10, 2022 C-Path and EFACTS Announce Data Sharing Agreement Making RDCA-DAP the Largest Worldwide Database for Friedreich’s Ataxia TUCSON, Ariz., Nov. 10, 2022 — Critical Path Institute (C-Path) and the European Friedreich’s Ataxia Consortium for Translatio
November 9, 2022 Innovative Use of Healthcare Data, ERN Data Management Strategy Multistakeholder Workshop The presentations of the workshop sessions are now available. In order to download the presentations...